Results 91 to 100 of about 46,730 (243)

Use of phosphodiesterase 5 inhibitors is not associated with ocular adverse events. [PDF]

J Sex Med, 2023
Belladelli F, Li S, Zhang CA, Muncey W, Del Giudice F, Glover F, Seranio N, Basran S, Fallara G, Montorsi F, Salonia A, Eisenberg ML.   +11 more
europepmc   +1 more source

Slit2/Robo Signaling Restores Diabetic Erectile Function via Neurovascular Remodeling

Andrology, EarlyView.
ABSTRACT Background Diabetes mellitus‐induced erectile dysfunction (DMED) is a common and debilitating vascular‐neurogenic complication of diabetes. The poor responsiveness of DMED patients to phosphodiesterase type‐5 inhibitors underscores the need for therapies capable of restoring both endothelial integrity and cavernous nerve function.
Sen Fu, Peng Hu, Zizhong Yang, Zhenghui Jin, Xiaoyu Zhu, Tao Wang, Jihong Liu, Kai Cui   +7 more
wiley   +1 more source

Umbilical Cord Blood–Derived Extracellular Vesicles Enhance Neurovascular Regeneration and Improve Erectile Function in a Mouse Model of Bilateral Cavernous Nerve Injury

Andrology, EarlyView.
ABSTRACT Background Erectile dysfunction (ED) secondary to cavernous nerve injury (CNI), such as that occurring after radical prostatectomy, remains a significant clinical challenge, particularly among patients who do not respond to phosphodiesterase Type 5 inhibitors (PDE5i).
Minh Nhat Vo, Guo Nan Yin, Fitri Rahma Fridayana, Yan Huang, Limanjaya Anita, Ju‐Hee Kang, Ji‐Kan Ryu   +6 more
wiley   +1 more source

Advances in the treatment of Raynaud’s phenomenon

Vascular Health and Risk Management, 2010
Terri L LevienDrug Information Pharmacist and Clinical Associate Professor, College of Pharmacy, Washington State University Spokane, WA, USAAbstract: Raynaud’s phenomenon is a common condition characterized by vasospasm of the digital arteries
Terri L Levien
doaj  

Non‐canonical PKG1 regulation in cardiovascular health and disease

British Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source

Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon. [PDF]

Cochrane Database Syst Rev, 2023
Maltez N, Maxwell LJ, Rirash F, Tanjong Ghogomu E, Harding SE, Tingey PC, Wells GA, Tugwell P, Pope J.   +8 more
europepmc   +1 more source

PDE4D and PDE3B orchestrate distinct cAMP microdomains in 3T3‐L1 adipocytes

British Journal of Pharmacology, EarlyView.
Basal conditions: •Ins/PDE3B lowers cytoplasmic cAMP (cyt‐cAMP) without affecting plasma membrane cAMP (pm‐cAMP). •Insulin decreases lipid droplet cAMP (LD‐cAMP) independent of PDE3B. •FGF1/PDE4D modestly reduces both cyt‐ and pm‐cAMP, while PDE4D alone can modulate LD‐cAMP. ISO stimulation: •Ins/PDE3B has minimal impact on cyt‐cAMP.
Johannes Krier, David Spähn, David Arturo Juarez Lopez, Judith L. Nono, Judith Seigner, Lisa Jacob, Siegfried Ussar, Robert Lukowski, Andreas L. Birkenfeld, Gencer Sancar   +9 more
wiley   +1 more source

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz, Sophie Sprenger, Olga Schweigert, Sanika Mohagaonkar, Matti Walsdorff, Tanja Zeller, Filip Berisha, Viacheslav O. Nikolaev, Sergei D. Rybalkin   +8 more
wiley   +1 more source

Differential segment‐specific signalling pathways for guanylate cyclase C‐activated anion secretion in murine ileocolon

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Guanylate cyclase‐C (GC‐C) is the receptor for endogenous (uro)guanylin peptides, bacterial toxins and pharmacological analogues. Receptor activation leads to intestinal fluid loss, but also activates an antiproliferative pathway and is a promising target in colorectal cancer therapy.
Renjie Xiu, Johannes Reiner, Franz Hofmann, Azam Salari, Ursula Seidler   +4 more
wiley   +1 more source

Polarized effects of adenosine on blood–brain barrier integrity: Tightening from the luminal and opening from the abluminal side

British Journal of Pharmacology, EarlyView.
Background and Purpose Adenosine as a signalling molecule modifies blood–brain barrier (BBB) tightness in pathological conditions. Our aim was to investigate the direct and polarized effects of adenosine on the BBB using co‐culture and in vivo models. Experimental Approach The expression of adenosine receptors was measured by qRT‐PCR.
András Harazin, Gabriela Hurtado‐Alvarado, Lilla Barna, Arturo Contis‐Montes de Oca, Rocío Ruíz‐Manzano, Krisztián Laczi, András Kincses, Gergő Porkoláb, Gang Chen, Beatriz Gómez‐González, Mária A. Deli   +10 more
wiley   +1 more source